Literature DB >> 19238796

Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function.

Richard J Stanton1, Brian P McSharry, Melanie Armstrong, Peter Tomasec, Gavin W G Wilkinson.   

Abstract

With the enhanced capacity of bioinformatics to interrogate extensive banks of sequence data, more efficient technologies are needed to test gene function predictions. Replication-deficient recombinant adenovirus (Ad) vectors are widely used in expression analysis since they provide for extremely efficient expression of transgenes in a wide range of cell types. To facilitate rapid, high-throughput generation of recombinant viruses, we have re-engineered an adenovirus vector (designated AdZ) to allow single-step, directional gene insertion using recombineering technology. Recombineering allows for direct insertion into the Ad vector of PCR products, synthesized sequences, or oligonucleotides encoding shRNAs without requirement for a transfer vector Vectors were optimized for high-throughput applications by making them "self-excising" through incorporating the I-SceI homing endonuclease into the vector removing the need to linearize vectors prior to transfection into packaging cells. AdZ vectors allow genes to be expressed in their native form or with strep, V5, or GFP tags. Insertion of tetracycline operators downstream of the human cytomegalovirus major immediate early (HCMV MIE) promoter permits silencing of transgenes in helper cells expressing the tet repressor thus making the vector compatible with the cloning of toxic gene products. The AdZ vector system is robust, straightforward, and suited to both sporadic and high-throughput applications.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19238796     DOI: 10.2144/000112993

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  64 in total

1.  Adenovirus with hexon Tat-protein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors.

Authors:  Di Yu; Chuan Jin; Justyna Leja; Nadim Majdalani; Berith Nilsson; Fredrik Eriksson; Magnus Essand
Journal:  J Virol       Date:  2011-09-28       Impact factor: 5.103

2.  Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.

Authors:  Alison Tedcastle; Sam Illingworth; Alice Brown; Leonard W Seymour; Kerry D Fisher
Journal:  Mol Ther       Date:  2015-12-28       Impact factor: 11.454

3.  An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector.

Authors:  Dongming Zhou; Xiangyang Zhou; Ang Bian; Hua Li; Heng Chen; Juliana C Small; Yan Li; Wynetta Giles-Davis; Zhiquan Xiang; Hildegund C J Ertl
Journal:  Nat Protoc       Date:  2010-10-14       Impact factor: 13.491

Review 4.  Getting genetic access to natural adenovirus genomes to explore vector diversity.

Authors:  Wenli Zhang; Anja Ehrhardt
Journal:  Virus Genes       Date:  2017-07-15       Impact factor: 2.332

5.  Adeno-associated virus enhances wild-type and oncolytic adenovirus spread.

Authors:  Eduardo Laborda; Cristina Puig-Saus; Manel Cascalló; Miguel Chillón; Ramon Alemany
Journal:  Hum Gene Ther Methods       Date:  2013-10-08       Impact factor: 2.396

6.  Insertion of exogenous epitopes in the E3-19K of oncolytic adenoviruses to enhance TAP-independent presentation and immunogenicity.

Authors:  A Rodríguez-García; E Svensson; R Gil-Hoyos; C A Fajardo; L A Rojas; M Arias-Badia; A S I Loskog; R Alemany
Journal:  Gene Ther       Date:  2015-05-21       Impact factor: 5.250

7.  A Combinatory Strategy for Detection of Live CTCs Using Microfiltration and a New Telomerase-Selective Adenovirus.

Authors:  Yanchun Ma; Sijie Hao; Shuwen Wang; Yuanjun Zhao; Bora Lim; Ming Lei; David J Spector; Wafik S El-Deiry; Si-Yang Zheng; Jiyue Zhu
Journal:  Mol Cancer Ther       Date:  2015-01-14       Impact factor: 6.261

8.  Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy.

Authors:  Chuan Jin; Di Yu; Matko Čančer; Berith Nilsson; Justyna Leja; Magnus Essand
Journal:  Hum Gene Ther       Date:  2013-08       Impact factor: 5.695

9.  The combination of i-leader truncation and gemcitabine improves oncolytic adenovirus efficacy in an immunocompetent model.

Authors:  C Puig-Saus; E Laborda; A Rodríguez-García; M Cascalló; R Moreno; R Alemany
Journal:  Cancer Gene Ther       Date:  2014-01-17       Impact factor: 5.987

10.  Bioselection Reveals miR-99b and miR-485 as Enhancers of Adenoviral Oncolysis in Pancreatic Cancer.

Authors:  Maria Rovira-Rigau; Giulia Raimondi; Miguel Ángel Marín; Meritxell Gironella; Ramon Alemany; Cristina Fillat
Journal:  Mol Ther       Date:  2018-09-27       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.